“We are making progress towards anticipated multiple key milestones, including at least four regulatory decisions, up to nine phase three readouts, and a significant series of people thought program starts.”

In context

“fic Officer, Chris Boshoff has moved both thoughtfully and quickly in reshaping our R&D organization to also center on oncology, vaccines, and inflammation immunology in addition to TheraMedics. Chris has enhanced his leadership team with some terrific additions who are recognized as leaders in their field. Patrizia Cavazzoni is our new Chief Medical Officer. Jeff Lagos is our new Chief Oncology Officer. And Jim List is our new Chief Internal Medicine Officer. These leaders each bring many years of experience, deep expertise, and a proven track record in guiding the discovery, development, and approval of practice-changing therapies, and they are an excellent addition to our already strong cast of leaders in R&D. We are on track for a strong year of anticipated pipeline catalysts in 2025. We are making progress towards anticipated multiple key milestones, including at least four regulatory decisions, up to nine phase three readouts, and a significant series of people thought program starts. With one of our key oncology programs, we aim to bring forward what could represent the first potential treatment advancement in more than thirty years for patients with BCG-naive high-risk non-muscle invasive bladder cancer. We are encouraged by a positive result of the pivotal phase three CREST trial of sarsallima in combination with BCG, a current standard of care. We presented the full data from this study this past weekend at the annual meeting of the America Neurological Association. Non-muscle invasive bladder cancer is a condition predominantly treated by urologists. In multiple market research and focus group studies, urologists stated a significant preference for a subcutaneous PDL1 because it can be used in their practices and eliminates the need to refer their patients to infu”